Savara Inc.

Savara Inc.

SVRA·NASDAQ

$5.32

+1.4%
HealthcareBiotechnology

Savara Inc., a clinical stage biopharmaceutical company, focuses on rare respiratory diseases. Its lead product candidate is molgramostim, an inhaled granulocyte-macrophage colony-stimulating factor, which is in Phase III development stage for the treatment of autoimmune pulmonary alveolar proteinosis. The company is headquartered in Austin, Texas.

At a Glance

Live Snapshot
Market Cap$1.09B
EPS-0.5300
P/E Ratio-10.05
Earnings Date08/06/2026

svra

Total Other Income Expenses Net

Last Annual Value

4.71M

3-Year CAGR

90%

5-Year CAGR

76%

10-Year CAGR

28%

Savara Inc.

Savara Inc. Competitors Analysis of Total Other Income Expenses Net

SVRA · NASDAQ
CompanyTotal Other Income Expenses Net
CAGR 3Y
CAGR 5Y
CAGR 10Y
SVRA logo
Savara Inc.
NASDAQ:SVRA
4.71M
-3.9%N/AN/A 
25.26M
24.2%99.9%41.1%
-31.95M
N/AN/AN/A
RZLT logo
Rezolute, Inc.
NASDAQ:RZLT
5.48M
9.3%22.4%79.5%
17.87M
N/AN/AN/A
9.70M
-8.3%108.4%N/A
12.81M
5.8%N/AN/A
11.75M
39.2%N/A62.6%
PROK logo
ProKidney Corp.
NASDAQ:PROK
13.49M
-15.1%483.2%N/A
Savara Inc.

Savara Inc. Fair Value Envelope

SVRA · NASDAQ

Our analysis suggests that SVRA has a fair value of HIDDEN per share in the Base Case projection. With shares currently trading at $5.3249, this represents a potential HIDDEN relative to our calculated worth for Savara Inc..

Intrinsic Value
Current Price: $5.3249